Prithviraj Bose, MD

Articles

Dr. Bose on Current Treatment Options for Essential Thrombocythemia

October 15th 2020

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

Dr. Bose on Novel Agents Under Investigation in Essential Thrombocythemia

September 17th 2020

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 9th 2020

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 8th 2020

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Bose on the Utility of Ruxolitinib in Myelofibrosis

June 6th 2020

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.

Dr. Bose on Novel Agents Under Investigation in Myelofibrosis

May 14th 2020

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Dr. Bose on Novel Agents Under Investigation in Myelofibrosis

May 14th 2020

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Dr. Bose on Treating Progression in Patients With Myelofibrosis

February 14th 2020

Prithviraj Bose, MD, discusses treatment for patients with progressive myelofibrosis.